|
IllnessDose |
Comments |
Drug |
Duration |
| UPPER RESPIRATORY TRACT INFECTIONS: Consider delayed antibiotic prescriptions.A- |
|
Influenza |
Annual vaccination is essential for all those at risk of influenza . For otherwise healthy adults, antivirals are not recommended. Treat ‘at risk’ patients, only when influenza is circulating in the community (notification by Public Health email), within 48 hours of onset. At risk: 65 years or over, chronic respiratory disease (including COPD and asthma) significant cardiovascular disease (not hypertension), immunocompromised, diabetes mellitus, chronic renal disease. Patients over 12 years use oseltamivir 75 mg oral capsule BD (for OD prophylaxis see Influenza ) or zanamivir 10 mg (2 inhalations by diskhaler) BD for 5 days. |
|||||||
|
Pharyngitis / sore throat / tonsillitis |
The majority of sore throats are viral; most patients do not benefit from antibiotics. Patients with 3 of 4 centor criteria (history of fever, purulent tonsils, cervical adenopathy, absence of cough) or history of otitis media may benefit more from antibiotics.A- Antibiotics only shorten duration of symptoms by 8 hours.A+ NNT = 30 (child) or 145 (adult) to prevent one case of otitis media.A+ Seven days treatment gives less relapse than three days.B+ |
|||||||
|
Recent evidence indicates that penicillin 500 mg TDS for 7 days is more effective than 3 days.B+ Twice daily higher dose can also be used.A- QDS may be more appropriate if severe.D |
phenoxymethylpenicillin first line |
500 mg BD-QDS |
7-10 days |
|||||
|
erythromycin if allergic to penicillin |
500 mg BD or 250 mg QDS (QDS less side-effects) |
5-10 days |
||||||
|
Otitis media (child doses) |
Many are viral. Resolves in 80% without antibiotics.A+ Poor outcome unlikely if no vomiting or temp <38.5oC.A- Use NSAID or paracetamol.A- Antibiotics do not reduce pain in first 24 hours, subsequent attacks or deafness.A+ NNT = 20 (>2y) and NNT = 7 (6-24m old) to get pain relief in one at 2-7 days.A+B+ |
amoxicillin first line |
<2 yrs 125 mg TDS 2-10 yrs 250 mg TDS >10 yrs 500 mg TDS |
3-7 days* 3-7 days* 3-7 days* |
||||
|
erythromycin if allergic to penicillin
Azithromycin 2nd line if allergic to penicillins co-amoxiclav 2nd line |
<2 yrs 125 mg QDS 2-8 yrs 250 mg QDS Other: 250-500 mg QDS 15-25kg 200 mg OD 26-35kg 300 mg OD 36-45kg 400 mg OD 1-6 yrs 156 mg TDS 6-12 yrs 312 mg TDS |
3-7 days* 3-7 days* 3-7 days* 3 days 3 days 3 days 3-7 days* 3-7 days* |
||||||
|
Rhinosinusitis acute or chronic |
Many are viral. Symptomatic benefit of antibiotics is small - 69% resolve without antibiotics; and 84% resolve with antibiotics.A+ Reserve for severeB+ or symptoms (>10 days).Cochrane review concludes that amoxicillin A+ and phenoxymethylpenicillin A+ have similar efficacy to the other recommended antibiotics. |
phenoxymethylpenicillin or amoxicillin or oxytetracycline or erythromycin or doxycycline |
500 mg TDS 500 mg TDS 250 mg QDS 250 mg QDS/500mg BD 200 mg stat/100 mg OD |
7-10 days 7-10 days 7-10 days 7-10 days 7-10 days |
||||
|
If failure to respond to first line antibiotics |
co-amoxiclav |
625 mg TDS |
7-10 days |
|||||
|
Laryngitis/ laryngtracheo bronchitis |
Caused by respiratory virus |
No antibiotic treatment |
||||||
|
|
||||||||
|
LOWER RESPIRATORY TRACT INFECTIONS |
||||||||
|
Note: Avoid tetracyclines in pregnancy. Low doses of penicillins are more likely to select out resistance. The quinolones ciprofloxacin and ofloxacin have poor activity against pneumococci. However, they do have use in PROVEN pseudomonal infections. Levofloxacin has some anti-Gram-positive activity but should not be needed as first line treatment. |
||||||||
|
Acute bronchitis |
Systematic reviews indicate antibiotics have marginal benefits in otherwise healthy adults.A+ onsider antibiotics in > 60 yrs or if underlying chest disease. Patient leaflets can reduce antibiotic use.B+ |
amoxicillin or oxytetracycline or doxycycline |
500 mg TDS 250–500 mg QDS 200 mg stat/100 mg OD |
5 days 5 days 5 days |
||||
|
Acute exacerbation of COPD |
30% viral, 30-50% bacterial Antibiotics not indicated in absence of purulent/mucopurulent sputum.B+ Most valuable if increased dyspnoea and increased purulent sputum.B+ In penicillin allergy use erythromycin if tetracycline contraindicated If clinical failure to first line antibiotics |
amoxicillin or oxytetracycline or doxycycline erythromycin co-amoxiclav |
500 mg TDS 250 mg QDS 200 mg stat/100 mg OD 250 – 500 mg QDS 625 mg TDS |
5-10 days 5-10 days 5-10 days 5-10 days 5-10 days |
||||
|
Community-acquired pneumonia - treatment in the community |
Start antibiotics immediately.B- If no response in 48 hours consider admission or add erythromycin first line or a tetracyclineC to cover Mycoplasma infection (rare in over 65s)In severely ill give parenteral benzylpenicillin before admissionC and seek risk factors for Legionella and Staph. aureus infection.D
|
amoxicillin and / or erythromycin |
500 mg - 1g TDS 500 mg QDS |
Up to 10 days Up to 10 days |
||||
|
oxytetracycline or doxycycline |
250-500 mg QDS 200 mg stat/100 mg OD |
Up to 10 days Up to 10 days |
||||||
|
MENINGITIS |
||||||||
|
Suspected meningococcal disease |
Transfer all patients to hospital immediately. Administer benzylpenicillin prior to admission, unless history of anaphylaxis,B- NOT allergy. Ideally IV but IM if a vein cannot be found. |
IV or IM benzylpenicillin
If allergic to penicillin Chloramphenicol
Ceftriaxone IV |
Adults and children 10 yr and over: 1200 mg Children 1 - 9 yr: 600 mg Children <1 yr: 300 mg
Adults: 50 to 100 mg / kg Children > 1yr: 12.5 to 25mg / kg Children 2 wks to 1 yr: 12.5 mg / kg Infants < 2 wks: 6mg / kg Adult: 2g Neonate: 20-50mg/kg Infant & child under 50kg: 20-50mg/kg Over 50kg: adult dose |
|
||||
|
Prevention of secondary case of meningitis: Only prescribe following advice from Public Health Doctor: 9 am – 5 pm: Birmingham and Solihull Health Protection Unit 0121 224 4670
Out of hours: Contact on-call Public Health doctor via Heartlands switchboard 0121 424 2000 |
||||||||
|
URINARY TRACT INFECTIONS UTI quick reference guide ESBL Prodigy |
||||||||
|
Note:. Amoxicillin resistance is common, therefore ONLY use if culture confirms susceptibility. In the elderly (>65 years), do not treat |
||||||||
|
Uncomplicated UTI ie no fever or flank pain |
Use urine dipstick to exclude UTI -ve nitrite and leucocyte 95% negative predictive value. Multi-resistant E. coli with ESBLs are increasing so perform culture in all treatment failures. There is less relapse with trimethoprim than cephalosporins or quinolonesA- |
trimethoprim B+or nitrofurantoinA- |
200 mg BD 50-100 mg QDS |
3 daysB+ 7 daysC in elderlyC |
||||
|
2nd line - depends on susceptibility of organism isolated eg nitrofurantoin amoxicillin, cefalexin, co-amoxiclav, quinolone ESBLs are multi-resistant but some remain sensitive to nitrofurantoin |
||||||||
|
UTI in pregnancy and men |
Send MSU for culture. Short-term use of trimethoprim (avoid 1st trimester) or nitrofurantoin (avoid third trimester, at term) in pregnancy is unlikely to cause problems to the foetus.B+ |
nitrofurantoin or trimethoprim 2nd line cefalexin or co-amoxyclav |
50 mg – 100 mg QDS 200 mg BD 500 mg BD 375 mg TDS |
7 days 7 days 7 days 7 days |
||||
|
Catheter UTI |
Only treat if systemic signs or symptoms of infection Bacterial eradication is not a realistic goal Consider whether catheter is clinically essential |
Co-amoxiclav 1st line 2nd line depends on sensitivity |
375mg TDS |
5 days |
||||
|
Children |
Send MSU for culture and susceptibility. Waiting 24 hours for results is not detrimental to outcome.A- |
trimethoprim or nitrofurantoin or cefalexin If susceptible, amoxicillin |
See BNF for dosage |
7 daysA+ |
||||
|
Acute pyelonephritis |
Send MSU for culture . A recent RCT showed 7 days ciprofloxacin was as good as 14 days co-trimoxazole.A-If no response within 24 hours admit. |
ciprofloxacinA- or co-amoxiclav If susceptible, trimethoprim |
500 mg BD 500/125 mg TDS 200 mg BD |
7 daysA- 14 days 14 days |
||||
|
Recurrent UTI women ≥ 3/yr |
Post coital prophylaxis is as effective as prophylaxis taken nightly. Prophylactic doses |
nitrofurantoin or trimethoprim |
50 mg 100 mg |
Stat post coital or od at night |
||||
|
GASTRO-INTESTINAL TRACT INFECTIONS |
||||||||
|
Eradication of Helicobacter pylori Helicobacter quick reference guide
Managing symptomatic relapse |
Eradication is beneficial in DU, GU and low grade MALTOMA, but NOT in GORD.A In NUD, 8% of patients benefit. Triple treatment attains >85% eradication.A+ Avoid clarithromycin or metronidazole if used in the past year for any infection.C DU/GU: Retest for helicobacter if symptomatic NUD: Do not retest, treat as functional dyspepsia In treatment failure consider endoscopy for culture & susceptibility.C Substitute oxytetracycline for clarithromycin or metronidazole and add bismuth salt.A- |
First lineA+ cheapest option lansoprazole PLUS metronidazole AND clarithromycin Alternative regimens A+ PPI OR ranitidine bismuth citrate PLUS 2 antibiotics: amoxicillin clarithromycinA+ metronidazole oxytetracycline |
30 mg BD 400 mg BD 250 mg BD
BD 400 mg BD 1 g BD 500 mg BD 400 mg BD 500 mg QDS |
All for 7 daysA 14 days in relapse or maltoma
|
||||
|
Gastroenteritis |
Fluid replacement essential. Antibiotic therapy is not usually indicated as it only reduces diarrhoea by 1-2 daysB+ and can cause antibiotic resistance.B+ Initiate treatment, on advice of microbiologist, if the patient is systemically unwell. Please send stool specimens from suspected cases of food poisoning. Notify and seek advice on exclusion of patients from, Public Health Doctor ( as above |
|||||||
|
Traveller’s diarrhoea |
Limit prescription of antibacterial to be carried abroad and taken if illness develops (ciprofloxacin 500 mg single dose) to people travelling to remote areas and for people in whom an episode of infective diarrhoea could be dangerous. |
|||||||
|
GASTRO-INTESTINAL TRACT INFECTIONS (Continued) |
||||||||
|
Threadworms |
Treat household contacts. Advise morning shower/baths and hand hygiene. Use piperazine in children under 2. Do not withhold from school |
mebendazole or piperazine |
100 mg 1-6 yrs 5ml spoon 3-12 mths 2.5ml spoon |
stat stat, repeat after 2 weeks |
||||
|
Antibiotic associated diarrhoea |
Send stool sample for Clostridium difficile toxin testing |
metronidazole |
400mg TDS |
10 days |
||||
|
Dysentry |
Send stool sample for testing. If history of recent travel, add in metronidazole |
ciprofloxacin |
500mg BD |
5 days |
||||
|
GENITAL TRACT INFECTIONS – UK NATIONAL GUIDELINES Vaginal discharge quick reference guide BASHH |
||||||||
|
Note: Refer patients with risk factors for STIs (<25y, no condom use, recent (<12mth) or frequent change of sexual partner, previous STI, symptomatic partner) to GUM clinic or general practices with level 2 or 3 expertise in GUM. |
||||||||
|
Vaginal candidiasis |
All topical and oral azoles give 80-95% cure.A- In pregnancy avoid oral azole.B In complicated cases (diabetes, recurrence or severe cases) send sample for culture and treat 7-14 days |
clotrimazole 10% or clotrimazole or fluconazole |
5 g vaginal cream 500 mg pessary 150 mg orally |
stat stat stat |
||||
|
Bacterial vaginosis |
A 7 day course of oral metronidazole is slightly more effective than 2 g stat.A+ Avoid 2g stat dose in pregnancy. Topical treatment gives similar cure ratesA+ but is more expensive. |
metronidazoleA+ or metronidazole 0.75% vag gelA+ or clindamycin 2% creamA+ |
400 mg BD 5 g applicatorful at night 5 g applicatorful at night |
7 days 5 days 7 days |
||||
|
Chlamydia trachomatis |
Tetracyclines are contra-indicated in pregnancy. Erythromycin and ciprofloxacin are less efficacious than doxycycline. Treat partners Refer contacts to GUM clinic |
doxycyclineA+ or oxytetracyclineA- erythromycin A-
azithromycinA+ |
100 mg BD 500 mg QDS 500 mg BD or 500 mg QDS 1 g stat |
7 days 7 days 14 days 7 days 1 hr before or 2 hrs after food |
||||
|
Trichomoniasis |
Refer to GUM. Treat partners simultaneously In pregnancy avoid 2g single dose metronidazole. Topical clotrimazole gives symptomatic relief (not cure). |
metronidazoleA-
clotrimazole |
400 mg BD or 2 g in single dose 100 mg pessary |
5-7 days
6 days |
||||
|
Pelvic Inflammatory Disease (PID) |
Essential to test for N. gonorrhoea (as increasing antibiotic resistance) and chlamydia. Microbiological and clinical cure are greater with ofloxacin than with doxycycline.A+ Refer contacts to GUM clinic |
metronidazole + ofloxacinB or metronidazole + doxycyclineB |
400 mg BD 400 mg BD 400 mg BD 100 mg BD |
14 days 14 days 14 days 14 days |
||||
|
Acute prostatitis |
4 weeks treatment may prevent chronic infection. Quinolones are more effective. |
ciprofloxacin or trimethoprimC |
500 mg BD 200 mg BD |
28 days 28 days |
||||
|
Urethritis |
Refer with partners to GUM |
Doxycycline First line
Ciprofloxacin + Azithromycin |
100mg BD
500mg 1g |
7 days
stat stat |
||||
|
Epididymitis |
A) Younger patient (< 35 years). Exclude sexually transmitted epididymitis (Chlamydia / Gonorrhoea) even in the absence of urethral discharge. Diagnosis and treatment (also partners) should be best managed by GUM referral. B) Older Patient (> 35 years). Underlying urological pathology common. Non-specific bacterial infections with coliforms, Pseudomonas,eneterococcus. May develop after urinary tract surgery or catheterisation. Treat with ciprofloxacin (500mg BD, 5 days) initially. If failure to respond (or develops increasing pain or swelling), infarction,abscess or pyocoele should be suspected warranting urgent referral to urology. |
|||||||
|
SKIN / SOFT TISSUE INFECTIONS |
||||||||
|
Impetigo
|
Systematic review indicates topical and oral treatment produces similar resultsA+ As resistance is increasing reserve topical antibiotics for very localised lesionsC or D Reserve Mupirocin for MRSA. |
flucloxacillin First or erythromycin line fusidic acid mupirocin |
Oral 500 mg QDS Oral 500 mg QDS Topically QDS Topically QDS |
7 days 7 days 5 days 5 days |
||||
|
Eczema |
Using antibiotics, or adding them to steroids, in eczema does not improve healing unless there are visible signs of infection. |
|||||||
|
Cellulitis |
In mild cellulitis flucloxacillin maybe used as single drug treatment.C Refer severe cases to consultant microbiologist In facial cellulitis use co-amoxiclavC In sacral or chronic wound associated cellulitis, add metronidazole |
flucloxacillin OR erythromycin alone
co-amoxiclav |
500 mg QDS 500 mg QDS
500/125 mg TDS |
7 – 14 days 7 – 14 days
7 - 14 days |
||||
|
Leg ulcers |
Bacteria will always be present. Antibiotics do not improve healing.A+ Culture swabs and antibiotics are only indicated if diabetic or there is evidence of clinical infection such as inflammation/redness/cellulitis; increased pain; purulent exudate; rapid deterioration of ulcer or pyrexia. Sampling for culture requires cleaning then vigorous curettage and/or aspiration. |
|||||||
|
|
Diabetic leg ulcer Refer for specialist opinion if severe infection. |
co-amoxiclav |
625 mg TDS |
7-10 days and review |
||||
|
Animal bite
Human bite |
Surgical toilet most important. Assess tetanus and rabies risk. Antibiotic prophylaxis advised for – puncture wound; bite involving hand, foot, face, joint, tendon, ligament; immunocompromised, diabetics, elderly, asplenic Antibiotic prophylaxis advised. Assess HIV/hepatitis B & C risk |
First line animal & human prophylaxis and treatment co-amoxiclavB- If penicillin allergic: metronidazole PLUS doxycycline or oxytetracycline (animal) or erythromycin (human) and review at 24 & 48 hrs |
375-625 mg TDS
200-400 mg TDS 100 mg BD 250-500 mg QDS 250-500 mg QDS |
7 days
7 days 7 days 7 days
|
||||
|
Conjunctivitis |
Most bacterial infections are self-limiting (64% resolve on placeboA+). They are usually unilateral with yellow-white mucopurulent discharge.Refer if secondary to trauma or contact lens use |
chloramphenicol 0.5% drops + 1% ointment fusidic acid |
2 hrly reducing to QDS at night 1% gel BD |
All for 48 hours after resolution |
||||
|
Scabies |
Treat whole body including scalp, face, neck, ears, under nails. Treat all household contacts. |
permethrinA+ |
5% cream |
2 applications one week apart |
||||
|
Dermatophyte infection of the proximal fingernail or toenail For children seek advice |
Take nail clippings Idiosyncratic liver reactions occur rarely with terbinafine. |
5% amorolfine nail lacquerB- terbinafineA- |
1-2x/weekly fingers toes 250 mg OD fingers toes |
6 months 12 months 6 – 12 weeks 3 – 6 months |
||||
|
Pulsed itraconazole monthly is recommended for infections with yeasts and non-dermatophyte moulds.C |
itraconazole |
200 mg BD fingers toes |
7 days monthly 2 courses 7 days monthly 3 courses |
|||||
|
Dermatophyte infection of the skin |
Take skin scrapings for culture. Treatment: 1 week terbinafine is as effective as 4 weeks azole. A-If intractable consider oral itraconazole. Discuss scalp infections with specialist. |
Topical 1% terbinafine A+ Topical undecenoic acid or 1% azoleA+ |
OD - BD 1-2x/daily |
1 weekA+ 4 – 6 weeksA+ |
||||
|
Herpes zoster/ Chicken pox & Varicella zoster/ shingles |
If pregnant seek advice re treatment and prophylaxis Chicken pox: Clinical value of antivirals minimal unless immunocompromised, severe pain, on steroids, secondary household case AND treatment started <24h of onset of rash.A- Shingles: Treatment indicated if: ophthalmic or predictors of post-herpetic neuralgia: >60 yA+, severe pain,A+ severe skin rash, prolonged prodomal painB+ AND <72h of onset of rash. |
aciclovir or valaciclovir |
800 mg 5x/day 1 g TDS Child doses – see BNF |
7 days 7 days
|
||||
References
The following references were used when developing these guidelines:
This guidance was initially developed by practitioners in South Devon, as part of the S&W Devon Joint Formulary Initiative, and Cheltenham & Tewkesbury Prescribing Group and modified by the PHLS South West Antibiotic Guidelines Project Team, PHLS Primary Care Co-ordinators and members of the Clinical Prescribing Sub-group of the Standing Medical Advisory Committee on Antibiotic Resistance. It was further modified following comments from Internet users, and information from systematic reviews as they have been published.
Grading of guidance recommendations
The strength of each recommendation is qualified by a letter in parenthesis.
|
Study design |
Recommendation |
|
Good recent systematic review of studies |
A+ |
|
One or more rigorous studies, not combined |
A- |
|
One or more prospective studies |
B+ |
|
One or more retrospective studies |
B- |
|
Formal combination of expert opinion |
C |
|
Informal opinion, other information |
D |
PRODIGY web http://www.prodigy.nhs.uk. BNF (No 40 September 2000), SMAC report - The path of least resistance (1998), SDHCT Medical Directorate guidelines + GU medicine guidelines, Plymouth Management of Infection Guidelines project LRTI and URTI.
UPPER RESPIRATORY TRACT INFECTIONS
Influenza
http://www.hpa.org.uk/infections/topics_az/influenza/flu.htm#Influenza
Oseltamir for influenza. Drug & Therapeutic Bulletin 2002;40:89-91. (Review of benefits of oseltamir in influenza)
Turner D, Wailoo A, Nicholson K et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. University of Leicester 2002.
Stephanie A. Call, MD, MSPH; Mark A. Vollenweider, MD, MPH; Carlton A. Hornung, PhD, MPH; David L. Simel, MD, MHS; W. Paul McKinney, MD. Does this patient have influenza? JAMA. 2005;293:987-997.
Pharyngitis/sore throat/tonsillitis
Centor RM, Whitherspoon JM Dalton HP, Brody CE, Link K. The diagnosis of strep throat in adults in the emergency room. Med Decision Making 1981;1:239-46.
Del Mar C & Glasziou P. Antibiotics for the symptoms and complications of sore throat. In: The Cochrane Library, Issue 2. 1998 Oxford: Update Software. Search date 1998; primary sources Index Medicus 1945-65. Medline 1966 to 1997; Cochrane Library 1997 Issue 4; hand search of reference lists of relevant articles.
Del Mar C. Sore throats and antibiotics: Applying evidence on small effects is hard; variations are probably inevitable. Brit Med J 2000;320:130-1.
Del Mar C & Glasziou P. Upper respiratory tract infections. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:369-70.
Lan AJ, Colford JM, Colford JMJ. The impact of dosing frequency on the efficacy of 10 day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A meta-analysis. Pediatr 2000;105(2):E19.
McIsaac WJ, Goel V, Slaughter PM, Parsons GW, Woolnough KV, Weir PT, Ennet JR. Reconsidering sore throats. Part 2: Alternative approach and practical office tool. Can Fam Physician 1997;43:495-500.
Prodigy Guidance @
http://www.prodigy.nhs.uk/guidance.asp?gt=Sore%20throat%20-%20acuteSwart Sjoerd, Sachs APE, Ruijs G, Gubbels JW, Hoes AW, de Melker RA. Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults. Brit Med J 2000;320:150-4.
Scottish Intercollegiate Guidelines Network. Management of sore throat and indications for tonsillectomy. 1999.
http://www.show.scot.nhs.uk/sign/home.htm.Interim UK guidelines for public health management of close community contacts of invasive Group A streptococcal disease http://www.hpa.org.uk/infections/topics_az/strepto/guidelines.htm
Otitis media
Dagan R, Klugman KP, Craig WA. Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001;47:129-140. (Discusses penetration of antibiotics in OM)
Damoiseaux RAMJ, Van Balen FAM, Hoes AW, de Melker RA. Antibiotic treatment of acute otitis media in children under two years of age: evidence based? Brit J Gen Pract 1998;48:1861-4.
Damoiseaux RAMJ, Van Balen FAM, Hoes AW, Verhiej TJM, de Melker RA. Primary care-based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years. Brit Med J 2000;320:350-4.
Glasziou IP, Del Mar CB, Sanders SC, Hayem M. Antibiotics for acute otitis media in children (Cochrane Review). In: The Cochrane Library 2003. Issue 2. Oxford. Update software.
Kozyrskj AL, Hildes Ristein E, Longstaffe SEA, Wincott JL, Sitar DS, Klassen TP et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA 1998;279:1736-42.
Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavey J. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 2001;322:336-42.
Little P. Gould C, Moore M, Warner G, Dunleavey J. Williamson I. Predictors of poor outcome and benefits from antibiotics in children with acute otitis media: pragmatic randomised trial. BMJ 2002;325:22-26.
O’Neill P & Roberts R. Acute otitis media. In: Clinical Evidence Concise. London. BMJ Publishing Group 2004;11:47-49
Rhinosinusitis
de Ferranti SD, Lonnidis JPA, Lau J, Anniger WV, Barza M. Are amoxicillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis. Brit Med J 1998;317:632-7. Search date May 1998; primary sources Medline 1966 – May 1998; manual search of Excerpta Medica: recent abstracts for Interscience Conference on Antimicrobial Agents & Chemotherapy 1993-1997 and references of all trails review articles and special issues for additional studies.
Del Mar C & Glasziou P. Upper respiratory tract infections. In: Clinical Evidence Concise. London. MBJ Publishing Group 2004;11:369-70.
Diagnosis and treatment of acute bacterial rhinosinusitis. Summary, Evidence Report/Technology Assessment: Number 9 March 1999. Agency for Health Care Policy & Research, Rockville MD. http://www.ahcpr.gov/clinic/sinussum.htm
Hansen JG, Schmidt H, Grinsted P. Randomised, double blind, placebo controlled trial of Penicillin V in the treatment of acute maxillary sinusitis in adults in general practice. Scan J Prim Health Care 2000;18:44-47.
International Rhinosinusitis Advisory Board. Infectious rhinosinusitis in adults. Classification, aetiology and management. Ear Nose & Throat Journal 1997;76 (12 Suppl):1-22.
Prodigy Guidance @
http://www.prodigy.nhs.uk/guidance.asp?gt=SinusitisWilliams Jr JW, Aguilar C, Cornell J, Chiquette E. Dolor RJ, Makela M, Holleman DR, Simel DL. Antibiotics for acute maxillary sinusitis (Cochrane Methodology Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
http://www.antibioticresistance.org.uk/ARFAQs.nsf/0/44BFE0C0107D0CC380256F350045B0F4?OpenDocument
LOWER RESPIRATORY TRACT INFECTIONS
Acute bronchitis
Becker L, Glazier R, McIsaac W, Smucny J. Antibiotics for acute bronchitis. In: The Cochrane Library, Issue 2, 1998. Oxford: Update software, search date 1997; primary sources Medline 1966 to 1996; Embase 1974.
Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults. Brit Med J 1998;316:906-10.
Wark P. Bronchitis (acute). In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:362-63.
Macfarlane J, Holmes W, Gard P, Thornhill D. Macfarlane R. Reducing antibiotic use for acute bronchitis in primary care: blinded, randomised controlled trail of patient information leaflet. BMJ 2002;324:91-4.
Treatment of cough available in Prodigy website:
http://www.prodigy.nhs.uk/guidance.asp?gt=Sore%20throat%20-%20acuteCOPD
Anthonisen MD, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Int Med 1987;106:196-204.
Calverley PMA, Walker P. Chronic obstructive pulmonary disease. Lancet 2003;362:1053-61. Excellent review on pathophysiology and management of COPD. Little detailed information on antibiotic treatment.
Chronic obstructive pulmonary disease. Management of COPD in adults in primary and secondary care. Clinical Guideline 12 February 2004.
www.nice.org.uk/CG012NICEguideline
Community-acquired pneumonia
BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001;56(Suppl 4):IV1-64.
Hopstaken RM, Muris JWM, Knottnerus JA, Kester ADM, Rinkens PELM, Dinant GJ. Contributions of symptoms, signs, enthrocyte sedimentation rate and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Brit J Gen Pract 2003;53:358-364.
Loeb M. Community-acquired pneumonia. In: Clinical Evidence Concise. London BMJ Publishing Group. 2004;11:364-66
J T Macfarlane and D Boldy. 2004 update of BTS pneumonia guidelines: what’s new? Thorax 2004 May; 59(5): 634 - 6
MENINGITIS
Cartwright KAV, Strang J Gossain S, Begg N. Early treatment of meningococcal disease. Brit Med J 1992;305:774.
Correla J & Hart CA. Meningococcal disease. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:206-07.
Pre-admission benzylpenicillin for suspected meningococcal disease: other antibiotics not needed in the GP bag. CDR Weekly 15 February 2001.
PHLS Meningococcus Forum, endorsed by the PHLS, Public Health Medicine Environment Group and Scottish Centre for Infection and Environmental Health. Guidelines for public health management of meningococcal disease in the UK. Commun Dis Public Health 2002;5:187-204.
http://www.hpa.org.uk/cdph/issues/CDPHVol5/no3/Meningococcal_Guidelines.pdf
URINARY TRACT INFECTIONS
Elderly
Abrutyn E, Mossey J, Berlin JA, Boscia J, Levison M, Pitsakis P, Kaye D. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Int Med 1994:827-33.
Nicholl LE. Urinary tract infection. In: Infection Management for Geriatrics in Long-term Care Facilities. Eds Yoshikawa TT, Ouslander JG. Marcel Dekker. New York. 2002:173-95.
Carson C, Naber KG, Role of fluoroquinolones in the treatment od serious bacterial urinary tract infections. Drugs 2004; 64(12): 1359 - 73
Uncomplicated UTI
Charlton CAC, Crowther A, Davies JG, Dynes J, Howard MWA, Mann PG, Rye S. Three day and ten day chemotherapy for urinary tract infections in general practice. Brit Med J 1976;1:124-6.
Christiaens TCM, Meyere M De, Vershcraegen G. Peersman W, Heytens S. Maeseneer JM De. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Brit J Gen Pract 2002;52:729-34.
Davey PG, Steinke D. MacDonald TM, Phillips G, Sullivien F. Not so simple cystitis: How should prescribers be supported to make informed decisions about the increasing prevalence of infections caused by drug resistant bacteria? Brit J Gen Pract 2000;50:143-46.
Ellis R & Moseley DJ. A comparison of amoxicillin, co-trimoxazole, nitrofurantoin, macrocrystals and trimethoprim in the treatment of lower urinary tract infections. Management of UTIs. Ed. LH Harrison. 1990. Royal Society of Medicine Services International Congress & Symposium Series No. 154, publishers RSM Services Ltd. pp 45-52.
Gossius G Vorland L. The treatment of acute dysuria-frequency syndrome in adult women: double blind randomized comparison of three day versus ten day trimethoprim therapy. Curr Ther Res 1985;37(1):34-42.
Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 2000;61:353-64.
Hiscoke C, Yoxall H, Greig D, Lightfoot NF. Validation of a method for the rapid diagnosis of urinary tract infection suitable for use in general practice. Brit J Gen Pract 1990;40:403-5.
Hummers-Pradier E. Kocken MM. Urinary tract infections in adult general practice patients. Brit J Gen Pract 2002;52:752-61.
Livermore D, & Woodford N. Laboratory detection of bacteria with extended-spectrum beta-lactamases. CDR Weekly
2004;14 No. 27.
McCarty JM, Richard G, Huck W, Tucker RM, Toxiello RL, Shan M, Heyd A, Echols RM. A randomised trial of short-course ciprofloxacin, ofloxacin or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med 1999;106:292-9.
UTI in pregnancy
Information from the National Teratology Information Service (Tel: 0191 230 2036, Fax: 0191 232 7692) states:
Trimethoprim is a folate antagonist. In some women low folate levels have been associated with an increased risk of malformations. However, in women with normal folate status, who are well nourished, therapeutic use of trimethoprim for a short period is unlikely to induce folate deficiency.
A number of retrospective reviews and case reports indicate that there is no increased risk of foetal toxicity following exposure to nitrofurantoin during pregnancy. Serious adverse reactions eg peripheral neuropathy, severe hepatic damage and pulmonary fibrosis are extremely rare. Nitrofurantoin can cause haemolysis in patients with G6PD deficiency. Foetal erythrocytes have little reduced glutathione and there is a theoretical possibility that haemolysis may occur. However, haemolytic disease of the new-born has not been reported following in utero exposure to nitrofurantoin.
Children
Larcombe J. Urinary tract infections in children. In: Clinical Evidence Concise. London. BMJ Publishing Group 2004;11:87-90.
Acute pyelonephritis
Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J and Church DA. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. A randomized trial. JAMA 2000;283:1583-90. Evidence for 7 days ciprofloxacin.
Warren JW, Abrutyn E. Hebel JR et al Guidelines for antimicrobial treatment of uncomplicated bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29:745-58.
GASTRO-INTESTINAL TRACT INFECTIONS
Eradication of Helicobacter pylori
Bazzdi F. Pozzato P. Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter 2002;7 (Suppl 1):43-49.
British Society of Gastroenterology (1996) Dyspepsia Management Guidelines 1 pp1-8.
de Boer WA, Tytgat GNJ. Treatment of Helicobacter pylori infection. Brit Med J 2000;320:31-4.
Delaney B, Moayyedi P, Forman D. Helicobacter pylori infection. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:107-09.
NICE dyspepsia guidance. August 2004. Evidence indicates once daily PPI plus metronidazole 400mg BD + clarithromycin 250mg BD is as effective as using BD PPI or 500mg clarithromycin. This regimen is cheaper than using BD PPI or higher dose clarithromycin.
http://www.nice.org.uk/pdf/CG017fullguideline.pdfProdigy dyspepsia guidelines:
http://www.prodigy.nhs.uk/guidance.asp?gt=Dyspepsia%20-%20proven%20DU%20or%20GU
Gastroenteritis
de Bruyn G. Diarrhoea. In: Clinical Evidence Concise. London. BMJ Publishing Group2004;11:187-88.
Farthing M, Feldman R, Finch R, Fox R, Leen C, Mandal B, Moss P, Nathwani D, Nye F, Percival A, Read R, Ritchie L, Todd WT, Wood M. J of Infect 1996;33:143-52. The management of infective gastroenteritis in adults. A consensus statement by an expert panel convened by the British Society for the Study of Infection.
Gastroenteritis guidance in Prodigy:
http://www.prodigy.nhs.uk/guidance.asp?gt=GastroenteritisGoodman LJ, Trenholme GM, Kaplan RL el al. Empiric antimicrobial therapy of domestically acquired acute diarrhoea in urban adults. Arch Intern Med 1990;150:541-6.
Traveller’s diarrhoea
What to do about Traveller’s diarrhoea. Drugs & Therapeutic Bulletin 2002;40:36-38.
GENITAL TRACT INFECTIONS
Epididymitis
Hagley M. Epididymo-orchitis and epididymitis: a review of causes and managementof unusual forms. Int J STD AIDS. 2003 Jun; 14(6): 372 - 7
General
Joesoef MR & Schmid G. Bacterial vaginosis. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:384-86
Low N. Genital chlamydial infection. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:387-89.
Mitchell H. Vaginal discharge – causes, diagnosis and treatment. BMJ 2004;328:1306-08. Short review
Ross JDC. Outpatient antibiotics for pelvic inflammatory disease. BMJ 2001;322:251-2.
Sabbaj J, Hoagland VL, Cook T. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. Scand J Infect Dis 1986;Suppl 48:48-53.
Sexually Transmitted Infections 1999;75:Suppl 1. UK National Guidelines on Sexually Transmitted Infections and Closely Related Conditions. These guidelines are fully comprehensive and extensively referenced. Also available on the web.
http://www.bashh.org/guidelines/ceguidelines.htmWalker CK, Workowski KA, Washington AE, Soper DE, Sweet RL. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and preventions guidelines for treatment of sexually transmitted diseases. Clin Infect Dis 1999;28:529-36.
SKIN/SOFT TISSUE INFECTIONS
Impetigo
Sladden MJ, Johnston GA. Common skin infections in children. BMJ. 2004 Jul 10; 329 (7457): 95-9
Koning S, Verhagen AP, van Suijlekom-Smit LW, Morris A, Butler CC, van der Wouden JC. Interventions for impetigo. Cochrane database syst rev. 2004; (2):CD003261
Smethurst D & Macfarlane S. Atopic eczema. In: Clinical Evidence. London. BMJ Publishing Group. Available on web only.
http://127.0.0.1:49152/lpBinCE/lpext.dll?f=templates&fn=main-hit-h.htm&2.0George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Brit J Gen Pract 2003;53:480-87. (No difference between topical mupirocin and fusidic acid, no significant difference between topical and oral).
MeReC Bulletin. Acne. November 1994.
Eczema
Hoare C, Li Wan PA, Williams H (2000). Systematic review of treatments for atopic eczema. Health Technology Assessment 2000;4(37):1-191.
Prodigy guidance – atopic eczema.
http://www.prodigy.nhs.uk/guidance.asp?gt=Eczema%20-%20atopic#MI4_InfectedeczemaCellulitis
Dilemmas when managing cellulitis. Drugs & Therapeutic Bulletin 2003;41:43-46. (Review of the management of cellulitis)
Diabetic leg ulcer
Jeffcoate WJ, Harding KG. Review: Diabetic foot ulcers. Lancet 2003;361:1545-51.
Animal/human bites
Anderson CR. Animal bites. Guidelines to current management. Postgraduate Medicine 1992;92:134-49.
Goldstein EJC. Bites. In: Mandell GL, Bennett JE, Dolin R Eds. Principles and Practice of Infectious Diseases. Churchill Livingstone. 2000;2:3202-05.
Jones DA & Standbridge TN. A clinical trial using co-trimoxazole in an attempt to reduce wound infection rates in dog bite wounds. Postgraduate Medical J 1985;61:593-4.
Medeiros I, Saconat H. Antibiotic prophylaxis for mammalian bites (Cochrane Review). In: The Cochrane Library, Issue 2, 2001 Oxford: Update Software.
Prodigy website guidance.
http://www.prodigy.nhs.uk/guidance.asp?gt=Bites%20-%20human%20and%20animal#AntiobioticProphylaxis
Conjunctivitis
Smith J. Bacterial conjunctivitis. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:156.
ScabiesThe management of scabies. Drug & Therapeutics Bulletin 2002;40:43-46
Walker G, Johnstone P. Scabies. Clin Evid 2003 Dec;(10): 1910 - 8
Dermatophytes
Crawford F. Athlete’s foot and fungally infected toenails. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:403
Evans EGV & Sigurgeirsson B for the LION Study Group. Double blind randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Brit Med J 1999;318:1031-5.
Finlay AY. Skin and nail fungi – almost beaten. Don’t get confused by the ‘evidence’. Brit Med J 1999;319:71-2.
Fuller LC, Child FJ, Midgley G, Higgins EM. Diagnosis and management of scalp ringworm. BMJ 2004;326:539-41.
Getting rid of athlete’s foot. Drug & Therapeutics Bulletin 2002;40:53-54.
Hart R, Bell-Syer SEM, Crawford F, Torgerson DJ, Young P, Russell I. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. Brit Med J 1999;319:79-82.
Chickenpox/shingles
Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM, Feldman S et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991;325:1539-44.
Johnson RW.Herpes zoster – predicting and minimizing the impact of post-herpatic neuralgia. J Antimicrob Chemother 2001;47:Topic T11-8.
McKendrick MW & Balfour HH Jr. Acyclovir for childhood chickenpox. Controversies in management. Brit Med J 1995;310:108-110.
Prodigy Guidance – Shingles & postherpetic neuralgia. April 2002. At
www.prodigy.nhs.uk and go to guidance list.Swingler G. Chicken Pox. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:180-82.
Wareham D. Post herpetic neuralgia. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2004;11:208-10.
|
|